CVA
MCID: CRB039
MIFTS: 69

Cerebrovascular Disease (CVA)

Categories: Blood diseases, Cardiovascular diseases, Neuronal diseases

Aliases & Classifications for Cerebrovascular Disease

MalaCards integrated aliases for Cerebrovascular Disease:

Name: Cerebrovascular Disease 12 54 15
Cerebrovascular Disorders 43 71
Cerebrovascular Accident 12 71
Cerebrovascular Disorder 12 17
Stroke 12 43
Cva 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6713
NCIt 49 C2938 C3390
SNOMED-CT 67 62914000 82797006
UMLS 71 C0007820 C0038454

Summaries for Cerebrovascular Disease

Disease Ontology : 12 An vascular disease that is characterized by dysfunction of the blood vessels supplying the brain.

MalaCards based summary : Cerebrovascular Disease, also known as cerebrovascular disorders, is related to cerebral amyloid angiopathy, app-related and cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1, and has symptoms including seizures, tremor and angina pectoris. An important gene associated with Cerebrovascular Disease is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Microglia Activation During Neuroinflammation: Overview. The drugs Ticlopidine and Glyburide have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are Decreased free cholesterol and Increased LDL uptake

Wikipedia : 74 Cerebrovascular disease includes a variety of medical conditions that affect the blood vessels of the... more...

Related Diseases for Cerebrovascular Disease

Diseases related to Cerebrovascular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2189)
# Related Disease Score Top Affiliating Genes
1 cerebral amyloid angiopathy, app-related 34.0 SERPINA3 APP APOE
2 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 33.7 NOTCH3 COL4A1 APP APOE
3 stroke, ischemic 33.6 SERPINA3 SELP PON1 PLAT NOTCH3 MTHFR
4 vascular dementia 33.4 SERPINA3 PON1 NOTCH3 MTHFR CRP APP
5 peripheral artery disease 33.3 SELP CRP APOE APOB APOA1 ACE
6 retinal vascular occlusion 33.2 SELP MTHFR CRP
7 grange syndrome 33.0 SELP PLAT MTHFR
8 respiratory failure 32.8 SERPINA3 CRP ACHE ACE
9 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 2 32.8 NOTCH3 CRP
10 cerebral atherosclerosis 32.5 MTHFR CRP APOE APOA1 ACE
11 intracranial embolism 32.5 PLAT CRP ACE
12 cerebral amyloid angiopathy, cst3-related 32.2 SERPINA3 APP APOE
13 col4a1-related familial vascular leukoencephalopathy 32.2 NOTCH3 COL4A1
14 carotid stenosis 32.2 SELP MTHFR CRP APOE ACE
15 transient cerebral ischemia 32.2 NOTCH3 MTHFR ACHE
16 vascular disease 32.1 SELP PON1 PLAT MTR MTHFR MIR21
17 dementia 31.9 SERPINA3 NOTCH3 APP APOE ACHE ACE
18 alzheimer disease 31.8 SERPINA3 PON1 MTR APP APOE APOB
19 hypercholesterolemia, familial, 1 31.7 CRP APOE APOB APOA1 ACE
20 homocysteinemia 31.7 PON1 MTR MTHFR CRP APOE
21 sleep apnea 31.7 SELP CRP APOE APOB ACE
22 migraine with or without aura 1 31.7 NOTCH3 MTHFR CRP ACE
23 intracranial thrombosis 31.7 SELP PLAT MTHFR
24 hyperlipoproteinemia, type iii 31.7 APOE APOB APOA1
25 peripheral vascular disease 31.6 SELP PLAT CRP APOB APOA1 ACE
26 coronary heart disease 1 31.6 SELP PON1 PLAT MTHFR CX3CR1 CRP
27 lipid metabolism disorder 31.6 PON1 CRP APOE APOB APOA1 ACE
28 aphasia 31.5 PLAT APP APOE
29 arteriosclerosis 31.5 SELP PON1 MIR21 CRP APOE APOB
30 aortic valve insufficiency 31.5 PON1 CRP ACE
31 angina pectoris 31.5 PLAT CRP APOA1 ACE
32 carotid artery disease 31.5 SELP PON1 PLAT CRP APOE APOB
33 eclampsia 31.5 MTHFR AGTR1 ACE
34 atherosclerosis susceptibility 31.5 SELP PON1 PLAT MTHFR CX3CR1 CRP
35 hydrocephalus 31.4 SERPINA3 PLAT MTHFR APP APOE ACE
36 patent foramen ovale 31.4 PLAT NOTCH3 MTHFR CRP ACE
37 arteries, anomalies of 31.4 SERPINA3 SELP PLAT MIR21 CRP APOE
38 intracranial berry aneurysm 31.4 SERPINA3 PLAT CRP APOE
39 coronary artery anomaly 31.4 SELP PON1 PLAT MIR21 CRP APOB
40 atrial heart septal defect 31.4 PLAT MTHFR CRP ACE
41 ischemia 31.4 SELP PON1 PLAT CX3CR1 APP ACE
42 arteriolosclerosis 31.3 SERPINA3 APP APOE
43 normal pressure hydrocephalus 31.3 SERPINA3 APP APOE ACE
44 binswanger's disease 31.3 NOTCH3 APP APOE ACHE
45 intracranial aneurysm 31.3 PLAT APOE ACE
46 mitral valve disease 31.3 CRP AGTR1 ACE
47 migraine with aura 31.3 NOTCH3 MTR MTHFR ACE
48 retinal vascular disease 31.3 MTHFR MIR21 CRP ACE
49 cardiogenic shock 31.3 PLAT CRP
50 platelet aggregation, spontaneous 31.2 SERPINA3 SELP PLAT

Comorbidity relations with Cerebrovascular Disease via Phenotypic Disease Network (PDN): (show all 37)


Active Peptic Ulcer Disease Acute Cystitis
Alzheimer Disease Anxiety
Aortic Valve Disease 1 Basilar Artery Insufficiency
Benign Essential Hypertension Bronchitis
Cerebral Atherosclerosis Cerebral Degeneration
Decubitus Ulcer Deficiency Anemia
Encephalopathy Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypertensive Encephalopathy
Hypothyroidism Intermediate Coronary Syndrome
Intracranial Embolism Intracranial Thrombosis
Iron Deficiency Anemia Labyrinthitis
Malignant Essential Hypertension Mitral Valve Disease
Osteoporosis Parkinson Disease, Late-Onset
Peripheral Vascular Disease Protein-Energy Malnutrition
Schizophreniform Disorder Sinoatrial Node Disease
Swallowing Disorders Transient Cerebral Ischemia
Vertebral Artery Insufficiency

Graphical network of the top 20 diseases related to Cerebrovascular Disease:



Diseases related to Cerebrovascular Disease

Symptoms & Phenotypes for Cerebrovascular Disease

UMLS symptoms related to Cerebrovascular Disease:


seizures, tremor, angina pectoris, edema, chest pain, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness, transient ischemic attacks, stereotypic symptoms

GenomeRNAi Phenotypes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 9.26 APOA1 APOB APOE SELP
2 Increased LDL uptake GR00340-A-1 8.8 APOA1 APOE SELP

MGI Mouse Phenotypes related to Cerebrovascular Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 ACE ACHE AGTR1 APOA1 APOB APOE
2 cardiovascular system MP:0005385 10.27 ACE AGTR1 APOA1 APOB APOE APP
3 growth/size/body region MP:0005378 10.21 ACE ACHE AGTR1 APOB APOE APP
4 mortality/aging MP:0010768 10.13 ACE ACHE AGTR1 APOB APOE APP
5 immune system MP:0005387 10.11 ACE AGTR1 APOB APOE APP COL4A1
6 nervous system MP:0003631 9.9 ACHE AGTR1 APOB APOE APP COL4A1
7 muscle MP:0005369 9.86 ACHE APOB APOE APP COL4A1 CX3CR1
8 reproductive system MP:0005389 9.65 ACE ACHE APOB APOE APP COL4A1
9 vision/eye MP:0005391 9.28 ACHE APOB APOE COL4A1 CX3CR1 MTHFR

Drugs & Therapeutics for Cerebrovascular Disease

Drugs for Cerebrovascular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ticlopidine Approved Phase 4 55142-85-3 5472
2
Glyburide Approved Phase 4 10238-21-8 3488
3
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
4
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
5
Nadroparin Approved, Investigational Phase 4
6
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
7
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
8
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
9
Galantamine Approved Phase 4 357-70-0 9651
10
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
11
Histamine Approved, Investigational Phase 4 51-45-6 774
12
Pantoprazole Approved Phase 4 102625-70-7 4679
13
Reteplase Approved, Investigational Phase 4 133652-38-7 65820
14
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
15
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
16
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
17
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
18
Bevacizumab Approved, Investigational Phase 4 216974-75-3
19
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
20
Phenindione Approved, Investigational Phase 4 83-12-5 4760
21
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
22
Ezetimibe Approved Phase 4 163222-33-1 150311
23
Enoxaparin Approved Phase 4 9005-49-6 772
24
Manidipine Approved, Investigational Phase 4 89226-50-6
25
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
26
Doxazosin Approved Phase 4 74191-85-8 3157
27
Paclitaxel Approved, Vet_approved Phase 4 33069-62-4 36314
28
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
29
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
30
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
31
Edaravone Approved, Investigational Phase 4 89-25-8 70335
32
Tirofiban Approved Phase 4 144494-65-5 60947
33
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
34
Propafenone Approved Phase 4 54063-53-5 4932
35
Haloperidol Approved Phase 4 52-86-8 3559
36
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
37
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
38
Ziprasidone Approved Phase 4 146939-27-7 60854
39
Quinidine Approved, Investigational Phase 4 56-54-2 441074
40
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
41
Triflusal Approved, Investigational Phase 4 322-79-2
42
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
43
Insulin aspart Approved Phase 4 116094-23-6 16132418
44
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
45
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
46
Reboxetine Approved, Experimental Phase 4 71620-89-8, 98769-81-4 123628 65856
47
Tizanidine Approved, Investigational Phase 4 51322-75-9 5487
48
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
49
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
50
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704

Interventional clinical trials:

(show top 50) (show all 9624)
# Name Status NCT ID Phase Drugs
1 Study of Influence of Timing on Motor Learning Unknown status NCT02048826 Phase 4
2 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease Unknown status NCT02444637 Phase 4 Rivastigmine
3 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
4 The Impact of NBP on the Collateral Circulation in Acute Acute Internal Carotid Artery(ICA)/Middle Cerebral Artery(M1) Occlusion Unknown status NCT02594995 Phase 4 NBP
5 The Early Diagnosis and Prevention of Ischemic Stroke and Cognition Decline Associated With Coronary Artery Disease Combined With Cerebral Artery Stenosis or Arrhythmia by 24-Hour Simultaneous Recorder of Electrocardiograph and Electroencephalography Unknown status NCT00247533 Phase 4
6 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
7 Efficacy of "Equistasi" on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident Unknown status NCT02714478 Phase 4
8 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
9 Effects of the Use of "de Novo" Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function Unknown status NCT01663805 Phase 4 Everolimus
10 Remifentanil for c-Section With General Anesthesia in Severe Preeclamptic Patients Unknown status NCT00567957 Phase 4 Remifentanil;Saline
11 Comparison of the Efficacy of Everolimus-Eluting Versus Sirolimus-Eluting Stent for Coronary Lesions Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
12 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
13 Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial Unknown status NCT02796664 Phase 4
14 A Randomized Controlled Study of Nifecardia SRFC (Nifedipine) and Adalat OROS (Nifedipine) in the Treatment of Patients With Essential Hypertension Unknown status NCT00173667 Phase 4 Nifedipine 30 mg GITS
15 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Astragalus Membranaceus in the Patients After Stroke With Fatigue Unknown status NCT01554787 Phase 4 Chinese Herb Astragalus membranaceus
16 Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome Unknown status NCT02604654 Phase 4 Yiqitongluo granule
17 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
18 The Effectiveness and Safety of Butylphthalide Soft Capsules in Secondary Prevention of Ischemic Stroke Trial Unknown status NCT00724724 Phase 4 Butylphthalide Soft Capsules;Aspirin
19 Effect of Active Telephone Calls in the Compliance of Hypertensive Patients With Treatment: An Open and Randomized Clinical Trial Unknown status NCT00813722 Phase 4 amlodipine (calcium chanel blocker) and losartan (at1 antagonist);atenolol (beta blocker) and hydrochlorothiazide (diuretic)
20 A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke. Unknown status NCT01863277 Phase 4 Melatonin;placebo
21 Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol Unknown status NCT02403349 Phase 4 Fimasartan;Valsartan;Atenolol
22 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
23 The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke. Unknown status NCT02618603 Phase 4 Botulinum toxin A;Triamcinolone Acetonide
24 Functional Electrical Stimulation (FES)-Assisted Walking: Enhancement of Voluntary Walking Function Among Persons With Severe Hemiplegia Post-Stroke Unknown status NCT00552916 Phase 4
25 A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism Unknown status NCT03090113 Phase 4 Shuxuetong Injection;Placebo Injection
26 Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke Unknown status NCT03252626 Phase 4 Alprostadil;Normal saline
27 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
28 Nimodipine Preventing Cognitive Impairment in Ischemic Cerebrovascular Events: A Randomized, Placebo-Controlled, Double-Blind Trial (NICE) Unknown status NCT01220622 Phase 4 Nimodipine;Placebo
29 The THERAPY Trial: The Randomized, Concurrent Controlled Trial to Assess the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
30 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
31 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
32 A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke Unknown status NCT01758536 Phase 4 Huatuo Zaizao Pills
33 Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD? Unknown status NCT01621451 Phase 4 aspirin and/or clopidogrel;aspirin and/or clopidogrel
34 The Hypertension in the Very Elderly Trial (HYVET) Unknown status NCT00122811 Phase 4 Indapamide SR 1.5mg; Perindopril 2-4mg
35 Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy Unknown status NCT02122367 Phase 4
36 Prospective, Randomized, Open-label, Blinded Endpoints, Multi-center Study to Evaluate the Efficacy of Modest Blood Pressure Reduction With Diovan® (Valsartan) in Acute Ischemic Stroke Unknown status NCT00874601 Phase 4 Diovan® (valsartan)
37 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
38 Efficacy of Creative Therapy for Stroke Patients Unknown status NCT01455155 Phase 4
39 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
40 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
41 Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke Unknown status NCT01198496 Phase 4 Losartan, Losartan and HCTZ, Amlodipine , Spironolactone
42 The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study Unknown status NCT02144831 Phase 4 anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
43 Randomized Controlled Trial to Evaluate Implanted Event Recorders for the First Diagnosis of Atrial Fibrillation in High-risk Patients Unknown status NCT01461434 Phase 4
44 Comparison of Two Strategies for Glycemic Control in Acute Ischemic Stroke Unknown status NCT00747279 Phase 4 Intensive insulin therapy
45 A Randomized Double Blind Placebo Control Study of Huang-Chi-Wu-Wu- Tang in Patients With Intracranial Arterial Stenosis Unknown status NCT01553643 Phase 4 Chinese Herb Huang-Chi-Wu-Wu-Tang;placebo
46 Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol Unknown status NCT02483169 Phase 4 cilostazol;Probucol;Aspirin;placebo of cilostazol;Placebo of aspirin
47 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
48 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
49 Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke Unknown status NCT02643784 Phase 4 Rosuvastatin
50 Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke Unknown status NCT01862978 Phase 4 Heparin;Nadroparin;Placebo

Search NIH Clinical Center for Cerebrovascular Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Pentoxifylline
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Cochrane evidence based reviews: stroke

Genetic Tests for Cerebrovascular Disease

Anatomical Context for Cerebrovascular Disease

MalaCards organs/tissues related to Cerebrovascular Disease:

40
Brain, Heart, Testes, Endothelial, Kidney, Bone, Lung

Publications for Cerebrovascular Disease

Articles related to Cerebrovascular Disease:

(show top 50) (show all 44390)
# Title Authors PMID Year
1
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 54 61
20485689 2010
2
Acetazolamide improves cerebral hemodynamics in CADASIL. 54 61
20227091 2010
3
The angiotensin II type 2 receptor in the brain. 54 61
19861353 2010
4
Lipids and carotid plaque in the Northern Manhattan Study (NOMAS). 54 61
20028534 2009
5
APOE-related mortality: effect of dementia, cardiovascular disease and gender. 54 61
18237822 2009
6
Apolipoprotein B levels, APOB alleles, and risk of ischemic cardiovascular disease in the general population, a review. 54 61
19200547 2009
7
Observation of the density and size of cells in hippocampus and vascular lesion in thalamus of GFAP-apoE transgenic mice. 54 61
19633698 2009
8
Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. 54 61
18985627 2009
9
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. 54 61
19417859 2009
10
CADASIL: extended polymorphisms and mutational analysis of the NOTCH3 gene. 54 61
19006080 2009
11
Report of two Chinese families and a review of Mainland Chinese CADASIL patients. 54 61
19167727 2009
12
Education attenuates the effect of medial temporal lobe atrophy on cognitive function in Alzheimer's disease: the MIRAGE study. 54 61
19542606 2009
13
MRI correlates of cognitive decline in CADASIL: a 7-year follow-up study. 54 61
19139365 2009
14
Age and apoE associations with complex pathologic features in Alzheimer's disease. 54 61
18653200 2008
15
Association of apolipoprotein E genotype and cerebrovascular disease risk factors in a Turkish population. 54 61
18576210 2008
16
Cystatin C expression in ischemic white matter lesions. 54 61
18261165 2008
17
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 54 61
18548143 2008
18
Association of blood pressure and genetic background with white matter lesions in patients with mild cognitive impairment. 54 61
18511756 2008
19
PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders. 54 61
17052804 2008
20
New biochemical markers in acute coronary syndromes. 54 61
18537608 2008
21
Specific P-selectin and P-selectin glycoprotein ligand-1 genotypes/haplotypes are associated with risk of incident CHD and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. 54 61
17420019 2007
22
Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. 54 61
17220293 2007
23
Polymorphisms in apolipoprotein B and risk of ischemic stroke. 54 61
17595251 2007
24
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. 54 61
17534460 2007
25
Silent brain infarction and platelet activation in obstructive sleep apnea. 54 61
17341649 2007
26
Increased plasma levels of asymmetric dimethylarginine in patients with carotid stenosis: no evidence for the role of the common FABP2 A54T gene polymorphism. 54 61
17212611 2007
27
Delapril plus indapamide: a review of the combination in the treatment of hypertension. 54 61
17506588 2007
28
A perspective on telmisartan and cardiovascular risk. 54 61
17938615 2007
29
Amyloid beta-peptide preconditioning reduces glutamate-induced neurotoxicity by promoting endocytosis of NMDA receptor. 54 61
17054909 2006
30
Cognitive impact of subcortical vascular and Alzheimer's disease pathology. 54 61
17192928 2006
31
Cerebrovascular disease, APOE epsilon4 allele and cognitive decline in a cognitively normal population. 54 61
16945218 2006
32
Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. 54 61
16894458 2006
33
Cognitive frailty: Predementia syndrome and vascular risk factors. 54 61
16023766 2006
34
Transient global amnesia in a patient with high and persistent levels of antiphospholipid antibodies. 54 61
16208431 2006
35
[The relationship between ApoE gene polymorphism and lipid parameters]. 54 61
16335008 2005
36
The spectrum of mutations for CADASIL diagnosis. 54 61
15995828 2005
37
Genetic variation of the intestinal fatty acid-binding protein 2 gene in carotid atherosclerosis. 54 61
16013194 2005
38
Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. 54 61
15681302 2005
39
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephaloapthy (CADASIL): a hereditary cerebrovascular disease, which can be diagnosed by skin biopsy electron microscopy. 54 61
15798438 2005
40
Leukocytosis and ischemic vascular disease morbidity and mortality: is it time to intervene? 54 61
15662026 2005
41
T280M and V249I polymorphisms of fractalkine receptor CX3CR1 and ischemic cerebrovascular disease. 54 61
15644279 2005
42
Carotid artery intima-media thickness and angiotensin-converting enzyme gene polymorphism in the offspring of parents with premature stroke. 54 61
15858957 2005
43
[Mutations of genes associated with thromboses in ischemic stroke in patients with primary antiphospholipid syndrome]. 54 61
16320685 2005
44
The FABP2 gene polymorphism in cerebrovascular disease. 54 61
15527447 2004
45
ACE genotype and cognitive decline in an African-Caribbean population. 54 61
15465635 2004
46
123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. 54 61
15471834 2004
47
Plasma adrenomedullin and carotid atherosclerosis in atherothrombotic ischemic stroke. 54 61
15361766 2004
48
Vascular injury in systemic sclerosis: angiotensin-converting enzyme insertion/deletion polymorphism. 54 61
15016346 2004
49
Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. 54 61
15161326 2004
50
Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects. 54 61
14512206 2003

Variations for Cerebrovascular Disease

Expression for Cerebrovascular Disease

Search GEO for disease gene expression data for Cerebrovascular Disease.

Pathways for Cerebrovascular Disease

Pathways related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.41 MTR MTHFR APOE APOB APOA1
2
Show member pathways
11.72 PLAT CX3CR1 COL4A1 APP
3
Show member pathways
11.57 COL4A1 APOE APOB APOA1
4
Show member pathways
11.56 SERPINA3 PLAT MTR MTHFR CRP APOE
5 11.23 SELP PLAT APOB
6 10.76 CX3CR1 APP APOE ACE
7 10.69 PLAT APP ACE
8 10.51 MEG3 HOTAIR

GO Terms for Cerebrovascular Disease

Cellular components related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.19 SERPINA3 PON1 PLAT MIR21 APP APOE
2 extracellular region GO:0005576 10.03 SERPINA3 PON1 PLAT NOTCH3 CRP COL4A1
3 cell surface GO:0009986 10 PLAT NOTCH3 CX3CR1 APP APOA1 ACHE
4 collagen-containing extracellular matrix GO:0062023 9.91 SERPINA3 PLAT COL4A1 APOE APOA1
5 endoplasmic reticulum lumen GO:0005788 9.88 COL4A1 APP APOE APOB APOA1
6 early endosome GO:0005769 9.86 APP APOE APOB APOA1
7 blood microparticle GO:0072562 9.8 SERPINA3 PON1 APOE APOA1
8 very-low-density lipoprotein particle GO:0034361 9.61 APOE APOB APOA1
9 endocytic vesicle lumen GO:0071682 9.58 APOE APOB APOA1
10 spherical high-density lipoprotein particle GO:0034366 9.55 PON1 APOA1
11 low-density lipoprotein particle GO:0034362 9.54 APOE APOB APOA1
12 chylomicron GO:0042627 9.5 APOE APOB APOA1
13 discoidal high-density lipoprotein particle GO:0034365 9.46 APOE APOA1
14 extracellular space GO:0005615 9.44 SERPINA3 SELP PON1 PLAT MIR21 CRP
15 intermediate-density lipoprotein particle GO:0034363 9.33 APOE APOB APOA1
16 high-density lipoprotein particle GO:0034364 9.26 PON1 APOE APOB APOA1

Biological processes related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.91 APP APOE APOB APOA1
2 platelet degranulation GO:0002576 9.81 SERPINA3 SELP APP APOA1
3 retinoid metabolic process GO:0001523 9.76 APOE APOB APOA1
4 artery morphogenesis GO:0048844 9.67 NOTCH3 APOE APOB
5 lipoprotein metabolic process GO:0042157 9.65 APOE APOB APOA1
6 high-density lipoprotein particle assembly GO:0034380 9.63 APOE APOA1
7 phospholipid efflux GO:0033700 9.63 APOE APOA1
8 cholesterol efflux GO:0033344 9.63 APOE APOB APOA1
9 amyloid precursor protein metabolic process GO:0042982 9.62 APOE ACHE
10 high-density lipoprotein particle clearance GO:0034384 9.62 APOE APOA1
11 methionine biosynthetic process GO:0009086 9.61 MTR MTHFR
12 positive regulation of cholesterol efflux GO:0010875 9.61 PON1 APOE APOA1
13 chylomicron remnant clearance GO:0034382 9.6 APOE APOB
14 very-low-density lipoprotein particle remodeling GO:0034372 9.59 APOE APOA1
15 regulation of Cdc42 protein signal transduction GO:0032489 9.58 APOE APOA1
16 negative regulation of long-term synaptic potentiation GO:1900272 9.58 CX3CR1 APP APOE
17 very-low-density lipoprotein particle clearance GO:0034447 9.57 APOE APOB
18 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.56 AGTR1 ACE
19 lipoprotein catabolic process GO:0042159 9.55 APOE APOB
20 positive regulation of amyloid fibril formation GO:1905908 9.54 APP APOE
21 low-density lipoprotein particle remodeling GO:0034374 9.54 APOE APOB AGTR1
22 positive regulation of phospholipid efflux GO:1902995 9.52 APOE APOA1
23 chylomicron assembly GO:0034378 9.5 APOE APOB APOA1
24 chylomicron remodeling GO:0034371 9.43 APOE APOB APOA1
25 positive regulation of cholesterol esterification GO:0010873 9.33 APOE APOA1 AGTR1
26 lipoprotein biosynthetic process GO:0042158 9.13 APOE APOB APOA1
27 cholesterol metabolic process GO:0008203 9.02 PON1 APP APOE APOB APOA1

Molecular functions related to Cerebrovascular Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heparin binding GO:0008201 9.67 SELP APP APOE APOB
2 amyloid-beta binding GO:0001540 9.63 APOE APOA1 ACHE
3 phospholipid binding GO:0005543 9.56 PON1 APOE APOB APOA1
4 lipid transporter activity GO:0005319 9.5 APOE APOB APOA1
5 lipoprotein particle binding GO:0071813 9.43 APOE APOA1
6 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.4 APOE APOA1
7 bradykinin receptor binding GO:0031711 9.16 AGTR1 ACE
8 low-density lipoprotein particle receptor binding GO:0050750 9.13 CRP APOE APOB
9 intermembrane cholesterol transfer activity GO:0120020 8.8 APOE APOB APOA1

Sources for Cerebrovascular Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....